Skip Nav Destination
Article navigation
Education|
February 1994
Long-term Intrathecal Morphine and Bupivacaine in Patients with Refractory Cancer Pain Results from a Morphine, Bupivacaine Dose Regimen of 0.5:4.75 mg/ml
Magnus Sjöberg, M.D.;
Magnus Sjöberg, M.D.
*Research Fellow and Resident in Anesthesiology.
Search for other works by this author on:
Petre Nitescu, M.D.;
Petre Nitescu, M.D.
†Staff Anesthesiologist, Senior Consultant.
Search for other works by this author on:
Lennart Appelgren, M.D., Ph.D.;
Lennart Appelgren, M.D., Ph.D.
‡Associate Professor of Clinical Anesthesiology.
Search for other works by this author on:
Ioan Curelaru, M.D., Ph.D.
Ioan Curelaru, M.D., Ph.D.
‡Associate Professor of Clinical Anesthesiology.
Search for other works by this author on:
Anesthesiology February 1994, Vol. 80, 284–297.
Citation
Magnus Sjöberg, Petre Nitescu, Lennart Appelgren, Ioan Curelaru; Long-term Intrathecal Morphine and Bupivacaine in Patients with Refractory Cancer Pain Results from a Morphine, Bupivacaine Dose Regimen of 0.5:4.75 mg/ml. Anesthesiology 1994; 80:284–297 doi: https://doi.org/10.1097/00000542-199402000-00008
Download citation file:
Citing articles via
Most Viewed
Related Articles
Neuropathologic Findings after Long-term Intrathecal Infusion of Morphine and Bupivacaine for Pain Treatment in Cancer Patients
Anesthesiology (February 1992)
Are the Preservatives Sodium Bisulfite and Ethylene Diaminetetraacetate Free from Neurotoxic Involvement?
Anesthesiology (September 1992)
Refractory Head and Neck Pain: A Difficult Problem and a New Alternative Therapy
Anesthesiology (February 1996)
Continuous Intracisternal and High Cervical Intrathecal Bupivacaine Analgesia in Refractory Head and Neck Pain
Anesthesiology (February 1996)
